News
Releases

BOSTON --(BUSINESS WIRE)--Jun. 4, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company’s common stock

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 BOSTON --(BUSINESS WIRE)--May 15, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results

PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open BOSTON --(BUSINESS WIRE)--May 5, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that

BOSTON --(BUSINESS WIRE)--Apr. 9, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16 th, 2026 at 12:45 p.m. ET. The live webcast of the presentation may be accessed

Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports key clinical milestones in endometrial and breast cancer BOSTON --(BUSINESS WIRE)--Mar. 30, 2026-- Sensei Biotherapeutics, Inc.

BOSTON --(BUSINESS WIRE)--Mar. 17, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei’s Board of Directors granted a new employee an option to purchase 166,435 shares of the Company’s common stock in connection with their employment

BOSTON --(BUSINESS WIRE)--Feb. 25, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company’s common stock in connection with

Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across